KOSDAQ - Delayed Quote KRW
Eutilex.Co.,Ltd (263050.KQ)
1,530.00
+6.00
+(0.39%)
At close: April 25 at 3:30:30 PM GMT+9
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Byoung S. Kwon Ph.D. | Founder & CEO | -- | -- | -- |
| Mr. Yeon-Ho Yoo | Chief Executive Officer | -- | -- | 1964 |
Eutilex.Co.,Ltd
Suite 408, 4th Floor
58 Gasan Digital 1-ro Geumcheon-gu
Seoul, 08591
South Korea
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Eutilex.Co.,Ltd. engages in the discovery and development of immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases. It develops EU101, a fully humanized anti-human 4-1BB monoclonal antibody; EU103, a fully humanized therapeutic monoclonal antibody; and EU501, an 4-1BB mAb-based, tumor antigen targeting bispecific antibodies. The company was founded in 2008 and is headquartered in Seoul, South Korea.
Corporate Governance
Eutilex.Co.,Ltd’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available